Nicotinamide Adenine Dinucleotide (NAD) Boosters for Longevity (Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR))

Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme for over 500 enzymatic reactions and the obligate substrate for sirtuins, PARPs, and CD38. Multiple independent labs have shown that tissue nicotinamide adenine dinucleotide falls by roughly 50% between ages 40 and 60 in humans, and that this decline is causally linked to age-related metabolic dysfunction, mitochondrial decay, and impaired DNA repair. Two oral precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — reliably raise blood nicotinamide adenine dinucleotide in humans by 1.5× to 2× at gram doses, and have generated one of the most contested debates in longevity science. This page walks through why nicotinamide adenine dinucleotide declines, how the precursors work, the David Sinclair vs Charles Brenner controversy over nicotinamide mononucleotide versus nicotinamide riboside, the controversial Slc12a8 transporter, and what the current human trial evidence actually shows.


Table of Contents

  1. What Nicotinamide Adenine Dinucleotide Does and Why It Matters
  2. Why Nicotinamide Adenine Dinucleotide Declines With Age
  3. CD38 and the Nicotinamide Adenine Dinucleotide Consumers
  4. The Precursor Cascade (Tryptophan to Nicotinamide Riboside to Nicotinamide Mononucleotide to Nicotinamide Adenine Dinucleotide)
  5. Nicotinamide Mononucleotide vs Nicotinamide Riboside: The Sinclair-Brenner Debate
  6. The Slc12a8 Transporter Controversy
  7. Human Clinical Trials
  8. Niacin and Nicotinamide as Cheaper Alternatives
  9. Doses Studied and Safety Findings
  10. Key Research Papers
  11. Connections
  12. Featured Videos

What Nicotinamide Adenine Dinucleotide Does and Why It Matters

Nicotinamide adenine dinucleotide is the most abundant non-protein redox molecule in living cells. It exists in two forms — oxidized nicotinamide adenine dinucleotide and reduced nicotinamide adenine dinucleotide (NADH) — and shuttles electrons between metabolic reactions. The nicotinamide adenine dinucleotide/reduced nicotinamide adenine dinucleotide ratio is the central indicator of cellular energy state.

Beyond its role as a redox cofactor, nicotinamide adenine dinucleotide is consumed (not just recycled) by three families of enzymes that are central to aging:

  1. Sirtuins (SIRT1–SIRT7): nicotinamide adenine dinucleotide-dependent deacylases that regulate gene expression, DNA repair, mitochondrial biogenesis, and metabolic flux. Discussed in depth on the Sirtuin Activators page. Sirtuin activity is rate-limited by nicotinamide adenine dinucleotide availability.
  2. PARPs (Poly-ADP-Ribose Polymerases): respond to DNA strand breaks by transferring ADP-ribose units from nicotinamide adenine dinucleotide onto target proteins. PARP1 alone can consume up to 80% of cellular nicotinamide adenine dinucleotide in heavily damaged cells, depleting the pool available for sirtuins and energy metabolism.
  3. CD38 and CD157: nicotinamide adenine dinucleotide glycohydrolases originally identified on lymphocyte surfaces but now known to be expressed on many cell types. CD38 activity rises with age and accelerates nicotinamide adenine dinucleotide decline.

Loss of nicotinamide adenine dinucleotide therefore simultaneously degrades energy metabolism, sirtuin signaling, and DNA repair — three of the hallmarks of aging at once. This is the mechanistic rationale for the nicotinamide adenine dinucleotide-precursor longevity hypothesis: if we can restore nicotinamide adenine dinucleotide, we can simultaneously restore mitochondrial function, sirtuin activity, and DNA repair capacity.

Back to Table of Contents

Multiple independent measurement methods (mass spectrometry of skin biopsies, NMR of muscle tissue, plasma assays) have converged on the conclusion that nicotinamide adenine dinucleotide declines with age. The precise magnitude varies by tissue and measurement method, but a roughly 50% decline in skeletal muscle and brain nicotinamide adenine dinucleotide between ages 40 and 60 is consistent across studies.

The decline is driven by three interacting processes:

  1. Reduced synthesis: enzymes in the salvage pathway (nicotinamide phosphoribosyltransferase, NAMPT, and nicotinamide mononucleotide adenylyltransferase, NMNAT) decline with age in some tissues, reducing the rate at which nicotinamide is recycled back into nicotinamide adenine dinucleotide.
  2. Increased consumption by CD38: CD38 expression on tissue-resident macrophages and other cells rises markedly with age, increasing nicotinamide adenine dinucleotide glycohydrolase activity in tissue.
  3. Increased PARP activity: cumulative DNA damage with age drives chronic PARP1 activation, which consumes nicotinamide adenine dinucleotide.

The result is a chronic energy-and-signaling deficit that aligns with the broader pattern of age-related mitochondrial dysfunction. Restoring nicotinamide adenine dinucleotide pharmacologically — in mice — has been shown to restore mitochondrial function, improve insulin sensitivity, improve exercise capacity, and partially reverse age-related decline in muscle and brain function. Whether the same effects translate to humans at the doses and timeframes used in clinical trials remains the central open question.

Back to Table of Contents

CD38 and the Nicotinamide Adenine Dinucleotide Consumers

The discovery that CD38 is the dominant age-related nicotinamide adenine dinucleotide consumer (Camacho-Pereira et al., Cell Metab 2016) shifted the field. Mice lacking CD38 do not show the age-related nicotinamide adenine dinucleotide decline; conversely, CD38 overexpression accelerates nicotinamide adenine dinucleotide loss and aging phenotypes. This implies that a CD38 inhibitor could raise nicotinamide adenine dinucleotide as effectively as supplementing precursors.

The candidate CD38 inhibitor with the most attention is apigenin, a flavonoid found in parsley, chamomile, celery, and onions. Apigenin inhibits CD38 in vitro and raises nicotinamide adenine dinucleotide in mice. Apigenin supplements are now sold by some longevity-focused vendors. Whether apigenin reaches plasma concentrations sufficient to inhibit CD38 in vivo at supplement doses is uncertain. Quercetin is also a CD38 inhibitor at high concentrations. 78c is an experimental CD38 inhibitor with stronger in vitro activity but no human data.

The implication for protocol design is that a comprehensive nicotinamide adenine dinucleotide-restoration strategy might combine precursor supplementation (nicotinamide riboside or nicotinamide mononucleotide, to drive synthesis) with CD38 inhibition (apigenin/quercetin, to reduce consumption), although this combined approach has not been rigorously tested in humans.

Back to Table of Contents

The Precursor Cascade (Tryptophan to Nicotinamide Riboside to Nicotinamide Mononucleotide to Nicotinamide Adenine Dinucleotide)

Cells make nicotinamide adenine dinucleotide through multiple parallel routes, all of which converge on the central molecule:

  1. De novo from tryptophan: dietary tryptophan can be converted to nicotinamide adenine dinucleotide through an 8-step kynurenine pathway. This is the slowest and least efficient route, but it explains why severe niacin deficiency requires extreme dietary restriction.
  2. From niacin (nicotinic acid): niacin is converted to nicotinamide adenine dinucleotide through the Preiss-Handler pathway. This is the route used by therapeutic high-dose niacin for dyslipidemia, and is highly efficient but causes the well-known flush.
  3. From nicotinamide (NAM): NAM enters the salvage pathway via NAMPT (the rate-limiting enzyme) which converts it to nicotinamide mononucleotide, which NMNAT then converts to nicotinamide adenine dinucleotide. This is the dominant pathway in most tissues most of the time.
  4. From nicotinamide riboside (NR): nicotinamide riboside enters cells through nucleoside transporters, gets phosphorylated by the nicotinamide riboside kinases (NRK1/NRK2) to nicotinamide mononucleotide, and then converted to nicotinamide adenine dinucleotide by NMNAT. This route bypasses NAMPT (which is the bottleneck in some tissues).
  5. From nicotinamide mononucleotide (NMN): nicotinamide mononucleotide can be converted directly to nicotinamide adenine dinucleotide by NMNAT. But because nicotinamide mononucleotide is a charged phosphate, it generally cannot cross cell membranes directly — a 2019 report (Grozio et al.) that a specific nicotinamide mononucleotide transporter (Slc12a8) exists is the subject of the controversy discussed below.

The cascade matters because it determines which oral precursor actually delivers nicotinamide adenine dinucleotide to the inside of cells. Nicotinamide riboside is the most established — Trammell's seminal 2016 Nat Commun paper showed nicotinamide riboside is uniquely orally bioavailable. Nicotinamide mononucleotide is also orally bioavailable, but Brenner's lab and others have argued that orally administered nicotinamide mononucleotide is mostly converted back to nicotinamide riboside (or to nicotinamide) in the gut before entering cells, making it effectively nicotinamide riboside by the time it reaches the cell interior. The counterargument from nicotinamide mononucleotide proponents hinges on the Slc12a8 transporter.

Back to Table of Contents

Nicotinamide Mononucleotide vs Nicotinamide Riboside: The Sinclair-Brenner Debate

The two leading nicotinamide adenine dinucleotide precursors on the market are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). They are chemically nearly identical — nicotinamide mononucleotide is nicotinamide riboside with an added phosphate group. The longevity supplement market has become deeply tribal about which is better, and the debate maps fairly cleanly onto two academic camps led by two prominent investigators. Some researchers in the field hold commercial interests in these products.

Charles Brenner (City of Hope) discovered nicotinamide riboside's role as a vitamin B3 precursor. Brenner's position: nicotinamide riboside is the only oral nicotinamide adenine dinucleotide precursor with rigorously characterized pharmacokinetics, nicotinamide mononucleotide is mostly degraded to nicotinamide riboside or nicotinamide before absorption, the claimed Slc12a8 nicotinamide mononucleotide transporter findings are flawed, and nicotinamide mononucleotide's marketing premium over nicotinamide riboside is not scientifically justified.

David Sinclair (Harvard) is the most prominent academic advocate for nicotinamide mononucleotide. Sinclair's position: nicotinamide mononucleotide is endogenously synthesized just before nicotinamide adenine dinucleotide, is one step closer in the salvage pathway, and the Slc12a8 transporter allows nicotinamide mononucleotide to enter cells directly. A 2019 Nature Metabolism paper from Shin-ichiro Imai's laboratory at Washington University (Grozio et al.) reported identification of Slc12a8 as the nicotinamide mononucleotide transporter.

What the data actually show, fairly read:

The honest summary: at the level of evidence currently available, both nicotinamide riboside and nicotinamide mononucleotide raise human blood nicotinamide adenine dinucleotide by similar amounts. Nicotinamide riboside has more mature pharmacokinetic and safety data. Nicotinamide mononucleotide has clearer regulatory uncertainty. Neither has been shown in any rigorous trial to extend human lifespan or even to slow biological aging on validated clocks. The evidence does not clearly favor one over the other, despite the partisan marketing on both sides.

Back to Table of Contents

The Slc12a8 Transporter Controversy

The Slc12a8 paper (Grozio et al., Nat Metab 2019) reported that mouse small intestine expresses a sodium-dependent nicotinamide mononucleotide transporter encoded by the Slc12a8 gene. The paper claimed that knockdown of Slc12a8 dramatically reduced nicotinamide mononucleotide uptake, and that the transporter was upregulated in conditions of nicotinamide adenine dinucleotide deficiency. The result was hailed by nicotinamide mononucleotide advocates as proof that nicotinamide mononucleotide reaches cells intact.

In 2019, a two-author letter in Nature Metabolism (Schmidt and Brenner) re-examined the Grozio data and argued that they do not show that Slc12a8 transports nicotinamide mononucleotide; the Grozio authors published a reply in the same issue defending their results. The original Slc12a8 paper also received an Author Correction in 2019 but was not retracted.

The current consensus position among biochemists is that Slc12a8 may or may not transport nicotinamide mononucleotide, but if it does, the activity is not as dramatic as the original paper claimed. Oral nicotinamide mononucleotide reaching cells likely does so primarily through degradation to nicotinamide riboside (which uses nucleoside transporters) or to nicotinamide (which crosses membranes freely), with at most a minor direct-NMN component.

What this means in practice: if nicotinamide mononucleotide works as a nicotinamide adenine dinucleotide precursor in humans (and the human blood-NAD evidence suggests it does), the mechanism is probably indirect through conversion to nicotinamide riboside or NAM in the gut. On that view, the effect would be expected to be similar to nicotinamide riboside at equivalent molar doses.

Back to Table of Contents

Human Clinical Trials

Human trial evidence on nicotinamide adenine dinucleotide precursors falls into three categories.

Pharmacokinetic and safety trials are well-established. Conze et al. (Sci Rep 2019) gave overweight but otherwise healthy adults 100, 300 or 1,000 mg/day of nicotinamide riboside or a placebo for 8 weeks. Whole-blood nicotinamide adenine dinucleotide rose by 22%, 51% and 142% at the three doses within 2 weeks and stayed up for the rest of the study. No flushing was reported, side effects did not differ from placebo, and LDL (“bad”) cholesterol did not rise. The study was funded by the company that makes the nicotinamide riboside product it tested. Martens et al. (Nat Commun 2018) ran a similar 6-week nicotinamide riboside study in healthy middle-aged adults with similar nicotinamide adenine dinucleotide elevation. Both established that nicotinamide riboside is safe at gram doses and reliably raises blood nicotinamide adenine dinucleotide.

Clinical biomarker trials are mixed. In Martens et al., nicotinamide riboside only tended to lower systolic blood pressure across the whole group; in an exploratory follow-up analysis of the 13 participants whose systolic pressure was 120–139 mmHg at the start, mean systolic pressure was 9 mmHg lower after nicotinamide riboside, which the authors described as a signal for future trials to test. Dollerup et al. (Am J Clin Nutr 2018) gave 2,000 mg/day nicotinamide riboside (1,000 mg twice daily) or placebo to 40 obese, insulin-resistant men aged 40–70 for 12 weeks and found NO improvement in insulin sensitivity or glucose metabolism and NO change in energy expenditure, fat breakdown or body composition — despite confirmed nicotinamide adenine dinucleotide elevation; no serious side effects were seen and safety blood tests were normal. A second paper from the same trial (Dollerup et al., J Physiol 2020) found that nicotinamide riboside did not change mitochondrial respiration, content or shape in the men's muscle. This was one of the most consequential null results in the field. Yoshino et al. (Science 2021) gave 250 mg/day nicotinamide mononucleotide to prediabetic postmenopausal women for 10 weeks and found that insulin-stimulated glucose uptake (measured with a whole-body clamp test) and insulin signaling in muscle increased after nicotinamide mononucleotide but not after placebo, but no change in body composition.

A 2026 systematic review (Yang et al., Nutrients) pooled 15 randomized trials of oral nicotinamide mononucleotide, at 250–2,000 mg a day for 14 days to 24 weeks. Nicotinamide mononucleotide did not increase side effects or serious side effects and did not significantly raise the liver enzymes ALT or AST. It had no significant effect on body weight, body mass index, fasting blood sugar, HbA1c (a three-month blood-sugar average), blood fats or systolic blood pressure; diastolic blood pressure fell slightly. The authors called for larger and longer trials.

Endpoint trials — trials of nicotinamide riboside or nicotinamide mononucleotide with clinical disease endpoints or aging biomarkers — are essentially absent. The longest published trial is approximately 6 months. No trial has reported epigenetic clock changes from nicotinamide riboside or nicotinamide mononucleotide. No trial has demonstrated reduced mortality, cardiovascular events, or cognitive decline.

The fair summary: nicotinamide adenine dinucleotide precursors are safe at the gram-dose range, reliably raise blood nicotinamide adenine dinucleotide, may modestly improve specific markers in specific populations (blood pressure in middle-aged adults on nicotinamide riboside, muscle insulin sensitivity in prediabetic women on nicotinamide mononucleotide), but have not been shown to deliver the broader healthspan or lifespan effects that the marketing implies. The biological hypothesis is strong; the clinical evidence is thin.

Back to Table of Contents

Niacin and Nicotinamide as Cheaper Alternatives

An underappreciated point is that niacin (nicotinic acid) and nicotinamide (NAM) are also nicotinamide adenine dinucleotide precursors — they cost a fraction of nicotinamide riboside or nicotinamide mononucleotide and are widely available as Vitamin B3. The reason the field has nonetheless focused on nicotinamide riboside and nicotinamide mononucleotide deserves examination.

Niacin causes the well-known prostaglandin-mediated "niacin flush" at doses above 100 mg, which limits chronic use. It is dramatically effective at raising nicotinamide adenine dinucleotide in tissue. Combinations of coenzyme Q10, niacin and acetyl-L-carnitine (ALCAR) are among the "mitochondrial cocktails" that practitioners describe using for people with mitochondrial disease. High-dose niacin (1–3 g/day) was historically used for dyslipidemia but fell out of favor when statins took over.

Nicotinamide (NAM) does not cause flushing and is cheap. The concern is that high-dose NAM directly inhibits sirtuins (as a product-inhibition effect of the sirtuin reaction). For this reason, NAM at gram doses may paradoxically reduce sirtuin activity even while raising nicotinamide adenine dinucleotide. Nicotinamide riboside avoids this because it enters the salvage pathway downstream of the inhibition point.

Some practitioners describe 500 mg/day of immediate-release nicotinic acid, taken at bedtime with aspirin beforehand to mute the flush, as raising nicotinamide adenine dinucleotide about as much as gram-dose nicotinamide riboside at roughly a twentieth of the cost; that comparison is their claim, not a trial result cited on this page. In their view, the newer precursors carry a marketing premium that is not fully matched by mechanistic advantage.

Back to Table of Contents

Doses Studied and Safety Findings

Doses given in the human trials on this page, and practices people describe:

Cautions:

  1. Cancer concern: nicotinamide adenine dinucleotide supports both sirtuin-mediated tumor suppression AND cellular energy that fuels cancer proliferation. Several animal studies have shown that nicotinamide riboside can accelerate growth of established tumors in some models. These animal findings matter most for people with an active cancer diagnosis or a recent cancer history.
  2. Liver enzyme elevation: rare, dose-dependent, reversible. Practitioners commonly check the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at the start and after 3 months on gram-dose precursors. The 2026 review of nicotinamide mononucleotide trials found no significant rise in either.
  3. Methylation burden: nicotinamide adenine dinucleotide precursors are ultimately disposed of through methylation (to N-methylnicotinamide), which consumes S-adenosylmethionine. Some practitioners suggest co-supplementing TMG (trimethylglycine, 500–1000 mg) on high-dose nicotinamide adenine dinucleotide precursor protocols, particularly in methylenetetrahydrofolate reductase-variant individuals.
  4. Drug interactions: high-dose niacin interacts with statins and blood-pressure drugs. Nicotinamide riboside and nicotinamide mononucleotide have fewer reported interactions but data are limited.

In summary: the biological hypothesis for nicotinamide adenine dinucleotide precursors is strong, the human evidence is suggestive in specific subgroups (prehypertension, prediabetes), the cost is meaningful ($30–$60/month for nicotinamide riboside; more for nicotinamide mononucleotide), and no rigorous trial has yet demonstrated lifespan or healthspan extension. Some people take them on the strength of the mechanism; others wait for endpoint data.

Back to Table of Contents

Key Research Papers

  1. Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 2004; 117:495–502. — PubMed PMID: 15137942
  2. Trammell SAJ et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun 2016; 7:12948. — PubMed PMID: 27721479
  3. Yoshino J et al. Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 2011; 14:528–536. — PubMed PMID: 21982712
  4. Mills KF et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab 2016; 24:795–806. — PubMed PMID: 28068222
  5. Camacho-Pereira J et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction. Cell Metab 2016; 23:1127–1139. — PubMed PMID: 27304511
  6. Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun 2018; 9:1286. — PubMed PMID: 29599478
  7. Dollerup OL et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr 2018; 108:343–353 (the null result) — PubMed PMID: 29992272
  8. Dollerup OL et al. Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men. J Physiol 2020; 598:731–754. — PubMed PMID: 31710095
  9. Grozio A et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab 2019; 1:47–57 (with subsequent Author Correction, Nat Metab 2019; 1:743, PMID 32694647) — PubMed PMID: 31131364
  10. Schmidt MS, Brenner C. Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter. Nat Metab 2019; 1:660–661. — PubMed PMID: 32694648
  11. Grozio A et al. Reply to: Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter. Nat Metab 2019; 1:662–665. — PubMed PMID: 32694650
  12. Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021; 372:1224–1229. — PubMed PMID: 33888596
  13. Conze D et al. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep 2019; 9:9772. — PubMed PMID: 31278280
  14. Yang W, Huang J, Tang Z, Chen C, Sun Y. Safety and metabolism-related outcomes of oral nicotinamide mononucleotide supplementation in adults: a systematic review and meta-analysis. Nutrients 2026; 18(14):2251. — PubMed PMID: 42514320
  15. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol 2014; 24:464–471. — PubMed PMID: 24786309
  16. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science 2015; 350:1208–1213. — PubMed PMID: 26785480
  17. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab 2018; 27:529–547. — PubMed PMID: 29514064
  18. Massudi H et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One 2012; 7:e42357. — PubMed PMID: 22848760
  19. Covarrubias AJ et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol 2021; 22:119–141. — PubMed PMID: 33353981

Back to Table of Contents

Connections

Back to Table of Contents